Artrya
Artrya is an ASX-listed medical technology company applying deep learning AI to analyze coronary CT angiography images for coronary artery disease diagnosis. Its Salix platform is sold to large hospital systems and cardiology/radiology clinicians, primarily in the US and Australia.
- Company typePublic
- Founded2019
- HeadquartersPerth, Australia
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Artrya does
Artrya Limited is an Australian medical technology company that applies deep learning AI to coronary CT angiography (CCTA) image analysis for the diagnosis of coronary artery disease (CAD). Founded in 2019 in Perth and listed on the ASX under ticker AYA, the company targets large hospital systems, cardiologists, and radiologists with its Salix platform, which detects and characterizes arterial plaque features—including low-attenuation plaque (LAP), spotty calcification, positive remodeling, and napkin-ring sign—that are not visible on standard coronary artery calcium scoring.
The technology stack consists of convolutional neural network (CNN) models for coronary artery centerline extraction and vessel wall segmentation, trained on thousands of expert-labeled scans from medical institutes in the US, Australia, and Canada. Salix is delivered as a web-based platform with multiple modules: Salix Coronary Anatomy (TGA-listed in Australia), Salix Coronary Plaque (FDA 510(k)-cleared August 2025), Salix Central USA (K243038), Salix Cloud (fee-per-scan commercial deployment), and Salix Coronary Flow (pursuing FDA clearance by June 2026). Outputs include structured quantitative data on plaque volume, stenosis estimation, calcium scoring, and standardized diagnostic reports.
Artrya runs a B2B enterprise field sales motion, primarily targeting large US healthcare systems following its August 2025 FDA clearance. Revenue derives from enterprise contracts with minimum commitments and a usage-based fee-per-scan cloud model, with first commercial fee-per-scan revenue reported in December 2025. Three US foundation partners—Northeast Georgia Health System, Cone Health, and Tanner Health—converted to commercial customers in Q2 2026 with minimum contracts totaling AUD 1.35 million. Six additional US healthcare systems are enrolled in the SAPPHIRE clinical study representing approximately 400,000 CCTA scans annually and an estimated $350 million revenue opportunity. Disclosed revenue is AUD 30,000, the company reports negative EPS, and it raised AUD 80 million in 2026 to fund US expansion.
Artrya firmographics
Firmographics- Name
- Artrya
- Legal name
- Artrya Limited ABN 53 624 005 741
- Website
- https://artrya.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Artrya is an ASX-listed medical technology company applying deep learning AI to analyze coronary CT angiography images for coronary artery disease diagnosis. Its Salix platform is sold to large hospital systems and cardiology/radiology clinicians, primarily in the US and Australia.
- Ownership category
- akta.pro rank
Artrya industry classification
Industry- Product category
- AI Cardiac Imaging Software
- NAICS
- Software Publishers (5132)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG), Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI), Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE), Medical Imaging AI (HDAAAEAH)
Keywords
Where Artrya is headquartered
LocationHeadquarters
- HQ city
- Perth
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Artrya business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Fee per Scan Revenue: Artrya generates revenue through a fee-per-scan model from the Salix Cloud platform. The company announced its first fee per scan revenue from Salix Cloud platform in December 2025. Minimum contracts with US foundation partners total AUD 1.35 million.
- Enterprise Software Contracts: Multi-year enterprise contracts with healthcare systems, including minimum commitment clauses. Three US foundation partners converted to commercial customers with minimum contracts totaling AUD 1.35 million.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Fee per scan pricing model for Salix Cloud platform |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Artrya product offering
Product offeringCore offering
Artrya develops and sells Salix, a web-based AI software platform that analyzes coronary CT angiography (CCTA) images using deep learning convolutional neural networks to detect, characterize, and quantify arterial plaque for the diagnosis of coronary artery disease. The platform identifies high-risk plaque features (low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign) that traditional coronary artery calcium scoring misses, and delivers standardized clinical reports and personalized 3D heart models to physicians and healthcare systems in the US and Australia.
Product overview
Artrya offers a unified AI-driven platform called Salix for coronary artery disease diagnosis, comprising multiple specialized modules. The core Salix platform provides CCTA image analysis using deep learning to detect and analyze arterial plaque. The product portfolio includes: Salix Coronary Plaque Module (FDA 510(k) cleared for automated plaque analysis and cardiac risk assessment), Salix Coronary Anatomy (Australian TGA registered for plaque, stenosis, and calcium analysis), Salix Central USA (FDA-cleared U.S. commercial version), Salix Coronary Flow Module (in development pursuing FDA clearance), and Salix Cloud Platform (cloud deployment enabling fee-per-scan commercial model). The modules work together as an integrated diagnostic support solution enabling physicians to detect atherosclerosis, visualize disease severity through 3D models, interpret plaque data for clinical decisions, generate standardized reports, and diagnose CAD within minutes.
Differentiator
Problem solved
Functional benefit
Brands
- Salix: AI-powered CCTA image analysis solution that empowers physicians to identify and analyze the extent and type of arterial plaque for coronary artery disease diagnosis. Salix includes modules for coronary anatomy analysis, coronary plaque assessment, and coronary flow analysis.
- Salix Coronary Anatomy
- Salix Coronary Plaque
- Salix Coronary Flow
- SAPPHIRE Study
Products and services
- Artrya Salix Platform Web-based AI software platform that uses deep learning convolutional neural networks to analyze coronary CT angiography (CCTA) images, enabling physicians to identify, quantify, and characterize arterial plaque for the diagnosis of coronary artery disease. Intended for trained medical professionals as an adjunctive tool that provides automated plaque feature detection (low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign), stenosis estimation, calcium scoring, personalized 3D heart models, and standardized clinical reports within minutes.
- Salix Coronary Plaque Module FDA 510(k) cleared (K243038) AI-powered automated analysis tool for coronary CT angiography that provides personalized cardiac risk assessments by detecting low-attenuation plaques and other high-risk plaque features not visible on standard coronary artery calcium scoring CT screenings.
- Salix Coronary Anatomy Module of the Salix platform listed on the Australian Register of Therapeutic Goods (ARTG ID 347719) that enables trained medical professionals to view and analyze cardiac CT data for determining the presence and extent of coronary plaques (atherosclerosis), stenosis quantification, and calcium scoring in patients undergoing CCTA for evaluation of coronary artery disease.
- Salix Cloud Platform Cloud-based deployment of the Salix AI platform that enables a fee-per-scan commercial revenue model for healthcare systems and supports clinical use by healthcare providers at scale.
Quantifiable outcome
- 90% of chest pain patients admitted to emergency department unnecessarily and should stay in primary care
- +5 more outcomes
Companies that use Artrya
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Artrya technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Artrya partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Northeast Georgia Health SystemcoreUS foundation partner that has been converted to a commercial customer. This is Artrya's second US order where Northeast Georgia Health System adopted Salix AI platform for cardiovascular diagnosis across its network in the US, aiming to enhance early detection and prevention of coronary artery disease using machine learning analysis of CT data.
- Cone HealthcoreUS foundation partner converted to commercial customer as part of three US foundation partners achieving commercial status with minimum contracts totaling AUD 1.35 million.
- Tanner HealthcoreUS foundation partner converted to commercial customer as part of three US foundation partners achieving commercial status with minimum contracts totaling AUD 1.35 million.
- SAPPHIRE Study Healthcare Systems (6 major US systems)coreSix major US healthcare systems enrolled in SAPPHIRE study representing approximately 400,000 CCTA scans annually with a potential revenue opportunity of roughly $350 million. These partnerships support FDA clinical validation and future commercial expansion.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Artrya competitors and assessment
Company assessmentDirect peers
- HeartFlow: HeartFlow develops AI-driven coronary CT analysis (FFR-CT) for non-invasive assessment of coronary artery disease. It is the closest direct competitor to Artrya, operating in the same CCTA AI category with US hospital customers and similar reimbursement-driven economics.
- Cleerly: Cleerly provides AI-based CCTA plaque analysis for coronary artery disease diagnosis and risk stratification. It directly competes with Artrya's Salix Coronary Plaque module and has established US commercial traction with health systems and payers.
- Elucid Bioimaging: Elucid Bioimaging offers AI software that quantifies atherosclerotic plaque from CCTA images, including characterization of plaque composition. It competes with Artrya in the AI-driven coronary plaque analysis category.
- Circle Cardiovascular Imaging: Circle CVI provides cardiac MR and CT post-processing software, including coronary analysis tools, sold to hospitals and imaging centers. It overlaps with Artrya's cardiac CT visualization and analysis capabilities.
Broad incumbents
- GE HealthCare: GE HealthCare offers the Edison AI platform and cardiac imaging suites integrated with CT scanners. It is a broad incumbent in cardiovascular imaging AI and competes for hospital imaging IT budgets alongside specialized vendors like Artrya.
- Siemens Healthineers: Siemens Healthineers provides AI-Rad Companion and syngo.via imaging IT, including cardiac CT applications. As a broad incumbent, it competes for enterprise imaging and AI budgets that Artrya targets with Salix.
- Philips: Philips IntelliSpace Portal and HeartNavigator cover cardiac CT analysis and AI-augmented reporting. As a broad incumbent, it competes with Artrya for hospital cardiology and radiology IT contracts.
- Canon Medical Systems (Vitrea): Canon Medical offers Vitrea advanced visualization software used for cardiac CT and coronary analysis. It competes with Artrya in post-processing and AI-enabled cardiac CT workflows within hospital imaging departments.
- Nanox AI (formerly Zebra Medical Vision): Nanox AI provides radiology AI algorithms across multiple imaging modalities including cardiac CT. It represents a broad AI-in-radiology incumbent with overlapping but more general-purpose capabilities than Artrya's specialized CCTA focus.
Emerging players
- Viz.ai: Viz.ai provides AI-driven imaging triage and coordination, primarily for stroke and now expanding into cardiology. It is an emerging AI imaging player with overlapping go-to-market motion into US hospital systems but a different primary clinical focus than Artrya.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Artrya social profiles
Digital presenceArtrya compliance and trust
Trust signalCompliance2 records
Artrya financial estimates
Financial estimateRevenue estimate
Valuation estimate
Artrya leadership team
Management profileNumber of profiles
Profiles10 records
Artrya subsidiaries and ownership
Company hierarchySubsidiaries1 record
Artrya funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Artrya M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Artrya
What does Artrya do?
Artrya develops and sells Salix, a web-based AI software platform that analyzes coronary CT angiography (CCTA) images using deep learning convolutional neural networks to detect, characterize, and quantify arterial plaque for the diagnosis of coronary artery disease. The platform identifies high-risk plaque features (low-attenuation plaque, spotty calcification, positive remodeling, napkin-ring sign) that traditional coronary artery calcium scoring misses, and delivers standardized clinical reports and personalized 3D heart models to physicians and healthcare systems in the US and Australia.
Is Artrya a public or private company?
Artrya is a public company. It is classified as public and is currently operating.
When was Artrya founded?
Artrya was founded in 2019. It employs 11 to 50 people.
Where is Artrya based?
Artrya is headquartered in Perth, Australia, in the Oceania region.
How does Artrya make money?
Two revenue lines are on record. Fee per Scan Revenue is the primary driver. The others are enterprise Software Contracts.
Who are Artrya's main competitors?
Direct peers on record are HeartFlow, Cleerly, Elucid Bioimaging and Circle Cardiovascular Imaging. Broad incumbents are GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems (Vitrea) and Nanox AI (formerly Zebra Medical Vision). Viz.ai is listed as an emerging player.
Does Artrya have an API?
No public API is recorded for Artrya.
What industry is Artrya in?
Artrya's product category is AI Cardiac Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage). Its NAICS code is 5132 and its SIC code is 3841.